The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis

被引:0
作者
Hiligsmann, Mickael [1 ,2 ,3 ,4 ]
Boonen, Annelies [1 ,2 ]
Rabenda, Veronique [4 ]
Reginster, Jean-Yves [4 ]
机构
[1] Maastricht Univ, Dept Internal Med, Div Rheumatol, NL-6229 HX Maastricht, Netherlands
[2] Maastricht Univ, CAPHRI Res Inst, NL-6229 HX Maastricht, Netherlands
[3] Maastricht Univ, Dept Clin Epidemiol & Med Technol Assessment, NL-6229 HX Maastricht, Netherlands
[4] Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium
关键词
adherence; compliance; cost-effectiveness; economic; osteoporosis; persistence; COST-EFFECTIVENESS; POSTMENOPAUSAL OSTEOPOROSIS; ORAL BISPHOSPHONATES; PATIENT ADHERENCE; FRACTURE RISK; TREATMENT PERSISTENCE; DIABETES-MELLITUS; ECONOMIC BURDEN; DRUG-THERAPY; IMPACT;
D O I
10.1586/ERP.12.8
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [41] Poor medication adherence to bisphosphonates and high self-perception of aging in elderly female patients with osteoporosis
    Wu, X.
    Wei, D.
    Sun, B.
    Wu, X. N.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (10) : 3083 - 3090
  • [42] Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan
    Makita, Kazuya
    Okano, Hiroya
    Furuya, Takefumi
    Urano, Tomohiko
    Hirabayashi, Hisashi
    Kumakubo, Takami
    Iwamoto, Jun
    JOURNAL OF BONE AND MINERAL METABOLISM, 2015, 33 (01) : 55 - 60
  • [43] Pharmacoeconomic concepts in antiplatelet therapy: Understanding cost-effectiveness analyses using clopidogrel as an example
    Weintraub, William S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2008, 13 (02) : 107 - 119
  • [44] When Multiple Objective Measures of Medication Adherence Indicate Incongruent Adherence Results: An Example with Pediatric Cancer
    Cain, Caitlin J.
    Meisman, Andrea R.
    Drucker, Kirstin
    Isaac, Evrosina I.
    Verma, Tanvi
    Griffin, Jordyn
    Rohan, Jennifer M.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (06)
  • [45] Non-Adherence to Anti-Osteoporosis Medication: Factors Influencing and Strategies to Overcome It. A Narrative Review
    Mangano, Giulia Rita Agata
    Avola, Marianna
    Blatti, Chiara
    Caldaci, Alessia
    Sapienza, Marco
    Chiaramonte, Rita
    Vecchio, Michele
    Pavone, Vito
    Testa, Gianluca
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (01)
  • [46] The importance of adherence to oral therapies in the field of oncology: the example of breast cancer
    Huiart, Laetitia
    Bardou, Valerie-Jeanne
    Giorgi, Roch
    BULLETIN DU CANCER, 2013, 100 (10) : 1007 - 1015
  • [47] Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study
    Hadji, P.
    Papaioannou, N.
    Gielen, E.
    Tepie, M. Feudjo
    Zhang, E.
    Frieling, I.
    Geusens, P.
    Makras, P.
    Resch, H.
    Moeller, G.
    Kalouche-Khalil, L.
    Fahrleitner-Pammer, A.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (10) : 2479 - 2489
  • [48] Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study
    P. Hadji
    N. Papaioannou
    E. Gielen
    M. Feudjo Tepie
    E. Zhang
    I. Frieling
    P. Geusens
    P. Makras
    H. Resch
    G. Möller
    L. Kalouche-Khalil
    A. Fahrleitner-Pammer
    Osteoporosis International, 2015, 26 : 2479 - 2489
  • [49] Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study
    Modi, A.
    Sen, S.
    Adachi, J. D.
    Adami, S.
    Cortet, B.
    Cooper, A. L.
    Geusens, P.
    Mellstrom, D.
    Weaver, J.
    van den Bergh, J. P.
    Nguyen, A. M.
    Sajjan, S.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (03) : 1227 - 1238
  • [50] The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis
    P. Hadji
    D. Felsenberg
    M. Amling
    L. C. Hofbauer
    J. A. Kandenwein
    A. Kurth
    Osteoporosis International, 2014, 25 : 339 - 347